Developer docs
API playgroundTry for free, no card

Search company profiles

Biosidus S.A.

Full company profile

uuid0009pgc

Namestring
Biosidus S.A.
Legal namestring
Biosidus S.A.
Websiteurl
biosidus.com.ar
Company typeenum
Private
Founded yearint
1983
Descriptiontext

Biosidus S.A. is an Argentine-headquartered biotechnology company founded in 1983 as a spin-off from the pharmaceutical firm Sidus, focused on the in-house development, manufacture, and global commercialization of biosimilar injectable biologics. The company operates from three integrated sites in Buenos Aires — Almagro (drug substance manufacturing and R&D laboratory), Bernal (fill-finish, lyophilization, and aseptic packaging), and Quilmes (international logistics and distribution) — and has developed nine commercial biosimilars covering erythropoietin (Hemax/Hemax LD, with 130 million cumulative doses sold), filgrastim (Neutromax, Lenobio), interferon beta (Blastoferon, Escleroferon, Bioferon), teriparatide (Osteofortil), somatropin (HHT), and a Phase III-stage agalsidase beta for Fabry disease (10th biosimilar), alongside select small molecules (azacitidine, bortezomib, fingolimod, buprenorphine). Its proprietary platform combines mammalian cell culture, bacterial fermentation, aseptic fill-finish, and an innovative transgenic cow biomanufacturing approach, supported by an in-house R&D team of approximately 17 PhD scientists.

The business model is B2B institutional: Biosidus sells through government tenders, hospital procurement, and public health systems in emerging markets (Latin America, Africa, Middle East, Asia, Eastern Europe), with pricing negotiated at institutional level and biosimilars priced 15-30% below originator biologics. Revenue is generated through direct sales via regional offices (Bogotá, Mexico City, Dubai, Bangkok, Barcelona) and through channel partners including Sandoz (Argentina distribution), Mubadala Bio (UAE, DiabTec platform), and tech-transfer/local-production partners in Algeria (>50% market share in certain segments) and Brazil. The company holds 300+ marketing authorizations and intentionally does not compete in the US, Canada, Western Europe, or Japan. Leadership is led by President & CEO Mariano de Elizalde, with a 7-member board, ~500 employees, and no disclosed external equity backers beyond a 2018 debt/structured round.

Short descriptiontext

Biosidus S.A. is an Argentine-headquartered biotechnology company developing, manufacturing, and distributing nine biosimilars and select small molecules for chronic and rare diseases across 60+ emerging market countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBuenos Aires, Argentina
HQ citystring
Buenos Aires
HQ countrystring
Argentina
HQ regionstring
Latin America
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosimilar pharmaceuticals, biological drug manufacturing, erythropoietin biosimilars, oncology biosimilars, biopharmaceutical distribution
Industry4 codes
PRIMARYHLAAAHAK
Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration)
SECONDARYHLAAAHAL
Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution)
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAFAL
Other Recombinant Protein Biosimilars (non-mAb, non-hormone)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biosimilar Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Proprietary Biosimilar Product Sales
TypeOne Time License
Description

Biosidus develops, manufactures, and commercializes its own portfolio of nine biosimilars. Revenue is generated through direct sales to healthcare systems, hospitals, pharmacies, and government procurement tenders across emerging markets in Latin America, Africa, Asia, and Eastern Europe.

biosidus.com.ar
2Distribution Licensing with Large Pharma Companies
TypeLicensing Royalties
Description

Biosidus signs licensing and distribution agreements with large pharmaceutical companies (e.g., Sandoz) for supplemental biologics. Biosidus supplies or licenses products while partners handle local commercialization and distribution, providing additional revenue streams and market access.

biosidus.com.ar
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Pricing details1 tier
1No public pricing available — sold through institutional/government procurement channels
ModelOtherBilling cadenceMulti-year contract
Notes

Biosimilars are sold through healthcare system procurement, hospital purchasing, and government tenders. Pricing is negotiated at institutional level and not publicly disclosed on the company's website.

biosidus.com.ar
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 14 records shown
1Hemax
Description

Erythropoietin (EPO) biosimilar for treating anemia associated with chronic kidney disease. Available in multiple formulations including lyophilized powder (LD) and higher doses.

biosidus.com.ar
+13 more records
Core offering1 text field

Biosidus is an Argentine biotechnology company that develops, manufactures, and commercializes a portfolio of nine biosimilars and several small molecule pharmaceuticals. The biosimilar portfolio covers erythropoietin, filgrastim, lenograstim, somatropin, teriparatide, interferon beta, and agalsidase beta, treating chronic kidney disease, multiple sclerosis, cancer, growth disorders, and rare lysosomal storage disorders. The company operates fully integrated manufacturing in Argentina (drug substance, fill-finish, and logistics) and distributes through direct sales offices, joint ventures, and licensing partners across more than 60 emerging markets in Latin America, Africa, the Middle East, Asia, and Eastern Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 130 million doses sold globally since launch for Hemax erythropoietin biosimilar
+5 more records
Product overview1 text field

Biosidus is a biotechnology company headquartered in Argentina that develops and commercializes a portfolio of 9 biosimilars and small molecule pharmaceuticals. The biosimilar portfolio includes erythropoietin products (Hemax and Hemax LD), filgrastim products (Neutromax and Lenobio), interferon beta products (Blastoferon, Escleroferon, and Bioferon), teriparatide (Osteofortil), and growth hormone (HHT). The small molecule portfolio includes azacitidine (Amilix), bortezomib (Bromadene), fingolimod (Biomonar), and buprenorphine (Restiva). The company operates integrated manufacturing facilities in Buenos Aires, Argentina, and distributes products to over 60 countries worldwide through a network of sales offices, joint ventures, and strategic partnerships.

Product and service14 records
1Hemax (Erythropoietin)
CategoryBiosimilar
Description

Erythropoietin biosimilar available in high-dose formulations (10K, 20K, 40K U.I.) for treating anemia associated with chronic kidney disease.

2Hemax LD
CategoryBiosimilar
Description

First lyophilized erythropoietin formulation that does not require cold chain storage. Available in low-dose formulations (1000-4000 U.I.) with over 130 million doses sold worldwide.

3Neutromax
CategoryBiosimilar
Description

Filgrastim biosimilar (rHuG-CSF) with 60% market presence in Argentina and leadership position in Brazil. Used for prevention of febrile neutropenia in chemotherapy patients.

4Lenobio
CategoryBiosimilar
Description

Glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF) for prevention of febrile neutropenia and mobilization of peripheral blood stem cells.

5Osteofortil
CategoryBiosimilar
Description

First teriparatide biosimilar with a comparative clinical trial of efficacy and safety versus innovator. Pre-filled syringes containing 20 mcg teriparatide for osteoporosis treatment.

6HHT (Somatropin)
CategoryBiosimilar
Description

Somatropin (human growth hormone) biosimilar available in lyophilized powder formulations (4 UI and 16 UI). Used for growth hormone deficiency in children with over 20 years of clinical experience.

7Blastoferon
CategoryBiosimilar
Description

Interferon beta 1a biosimilar (European standard) launched in Argentina in 2005. Pre-filled syringes with 22 mcg or 44 mcg doses for treating relapsing remitting multiple sclerosis.

8Escleroferon
CategoryBiosimilar
Description

Interferon beta 1a biosimilar with once-weekly dosing. Pre-filled syringes containing 30 mcg for multiple sclerosis treatment.

9Bioferon
CategoryBiosimilar
Description

Interferon biosimilar with broad-spectrum antiviral properties. Available in 3, 5, and 10 mIU vial formulations for reconstitution.

10Agalzyme
CategoryBiosimilar
Description

Agalsidase beta biosimilar for the treatment of Fabry disease. Available in 5 mg and 35 mg vials for intravenous infusion.

11Amilix
CategorySmall Molecule Pharmaceutical
Description

Azacitidine small molecule drug for adult patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia who are not eligible for hematopoietic stem cell transplantation.

12Bromadene
CategorySmall Molecule Pharmaceutical
Description

Bortezomib small molecule for front-line treatment of symptomatic multiple myeloma patients. Supplied as 3.5 mg sterile lyophilized powder for reconstitution.

13Biomonar
CategorySmall Molecule Pharmaceutical
Description

Fingolimod small molecule - first orally administered treatment for active relapsing remitting multiple sclerosis with over 10 years of real-life experience.

14Restiva
CategorySmall Molecule Pharmaceutical
Description

Buprenorphine transdermal patches for treatment of moderate to severe pain not responsive to non-opioid analgesics. Available in 5, 10, and 20 mg doses.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-24
Description

Biosidus signed a licensing and supply agreement with Mubadala Bio to introduce a portfolio of biologic therapies in the UAE through Mubadala Bio's biologics platform DiabTec. The agreement was signed at BIO International Convention 2026 and witnessed by Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi. The collaboration covers therapies across endocrinology, nephrology, and oncology including epoetin alfa, filgrastim, interferon beta, and somatropin.

2Sandoz
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Sandoz signed an agreement with Biosidus for the commercialization and distribution of current products and future launches in Argentina. This partnership extends Biosidus's market reach within Argentina through Sandoz's established pharmaceutical distribution network.

biosidus.com.ar
3Brazil Partner (Local Production)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership in Brazil enabling local production and distribution of Biosidus biosimilars, greatly enhancing market presence in one of Latin America's largest pharmaceutical markets.

biosidus.com.ar
4Algeria Partner (Packaging & Distribution)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Collaboration in Algeria for packaging and distribution of Biosidus biosimilars. This partnership established Biosidus as a dominant player with over 50% market share in certain segments in Algeria. The new facility in Algeria handles packaging initially and will eventually move toward full local production.

biosidus.com.ar
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
1Sandoz (Novartis)
TypeBroad incumbent
Description

Global biosimilar and generics leader with a deep biosimilar portfolio across oncology, immunology and endocrinology. Comparable as a biosimilar incumbent and Biosidus's distribution partner in Argentina, but with vastly broader molecule coverage and global reach.

TypeDirect peer
Description

South Korea-headquartered biosimilar pioneer, leading global supplier of infliximab, rituximab, trastuzumab and adalimumab biosimilars. Directly comparable to Biosidus as a vertically integrated biosimilar developer with strong emerging-market commercial footprint.

TypeDirect peer
Description

Joint venture between Samsung Biologics and Biogen developing biosimilars in oncology, immunology and ophthalmology (etanercept, infliximab, adalimumab, trastuzumab, ranibizumab). Comparable as a focused biosimilar developer competing on cost and quality in regulated and emerging markets.

4Shanghai Henlius Biotech
TypeEmerging player
Description

Chinese biosimilar developer with approvals in China, Europe and emerging markets (rituximab, trastuzumab, adalimumab, bevacizumab). Comparable as a newer biosimilar entrant expanding into Latin America, Africa and Asia with cost-competitive biologics.

5Hetero Drugs
TypeEmerging player
Description

Indian generics and biosimilar manufacturer with biosimilars in oncology (rituximab, bevacizumab) and a strong public-procurement track record in emerging markets. Comparable to Biosidus on cost-competitive biosimilars for tender-driven healthcare systems.

TypeDirect peer
Description

Indian generics and biosimilar company with biosimilars in oncology (rituximab, bevacizumab, pegfilgrastim) and a strong emerging-market commercial network. Comparable to Biosidus on biosimilar pipeline and emerging-market distribution model.

TypeDirect peer
Description

Argentina-headquartered biosimilar developer (part of Insud Pharma group) producing monoclonal antibody biosimilars for global markets. The closest geographic and business-model peer to Biosidus — Argentine biosimilar company with international commercialization.

TypeDirect peer
Description

India-based global biosimilar manufacturer with a portfolio covering insulin, trastuzumab, bevacizumab, pegfilgrastim and other recombinant biologics. Comparable to Biosidus as a focused biosimilar developer serving price-sensitive markets, though at much larger scale and broader molecule coverage.

TypeBroad incumbent
Description

Global generics and specialty pharma company with biosimilars (rituximab, trastuzumab) and broad emerging-market presence. Comparable on the biosimilar plus generics hybrid model and emerging-market distribution.

TypeBroad incumbent
Description

Global biopharmaceutical originator that has both developed originator biologics and a growing biosimilar portfolio (e.g., adalimumab, bevacizumab, trastuzumab). Comparable as a major player in both originator biologics and biosimilars, with manufacturing scale Biosidus aspires to.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biosidus S.A.

Biosimilar Pharmaceuticalsbiosidus.com.ar

Biosidus S.A. is an Argentine-headquartered biotechnology company developing, manufacturing, and distributing nine biosimilars and select small molecules for chronic and rare diseases across 60+ emerging market countries.

What Biosidus S.A. does

Biosidus S.A. is an Argentine-headquartered biotechnology company founded in 1983 as a spin-off from the pharmaceutical firm Sidus, focused on the in-house development, manufacture, and global commercialization of biosimilar injectable biologics. The company operates from three integrated sites in Buenos Aires — Almagro (drug substance manufacturing and R&D laboratory), Bernal (fill-finish, lyophilization, and aseptic packaging), and Quilmes (international logistics and distribution) — and has developed nine commercial biosimilars covering erythropoietin (Hemax/Hemax LD, with 130 million cumulative doses sold), filgrastim (Neutromax, Lenobio), interferon beta (Blastoferon, Escleroferon, Bioferon), teriparatide (Osteofortil), somatropin (HHT), and a Phase III-stage agalsidase beta for Fabry disease (10th biosimilar), alongside select small molecules (azacitidine, bortezomib, fingolimod, buprenorphine). Its proprietary platform combines mammalian cell culture, bacterial fermentation, aseptic fill-finish, and an innovative transgenic cow biomanufacturing approach, supported by an in-house R&D team of approximately 17 PhD scientists.

The business model is B2B institutional: Biosidus sells through government tenders, hospital procurement, and public health systems in emerging markets (Latin America, Africa, Middle East, Asia, Eastern Europe), with pricing negotiated at institutional level and biosimilars priced 15-30% below originator biologics. Revenue is generated through direct sales via regional offices (Bogotá, Mexico City, Dubai, Bangkok, Barcelona) and through channel partners including Sandoz (Argentina distribution), Mubadala Bio (UAE, DiabTec platform), and tech-transfer/local-production partners in Algeria (>50% market share in certain segments) and Brazil. The company holds 300+ marketing authorizations and intentionally does not compete in the US, Canada, Western Europe, or Japan. Leadership is led by President & CEO Mariano de Elizalde, with a 7-member board, ~500 employees, and no disclosed external equity backers beyond a 2018 debt/structured round.

Biosidus S.A. firmographics

Firmographics
Name
Biosidus S.A.
Legal name
Biosidus S.A.
Website
https://biosidus.com.ar
Company type
Private
Founded year
1983
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Biosidus S.A. is an Argentine-headquartered biotechnology company developing, manufacturing, and distributing nine biosimilars and select small molecules for chronic and rare diseases across 60+ emerging market countries.
Ownership category
akta.pro rank

Biosidus S.A. industry classification

Industry
Product category
Biosimilar Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAHAK
Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration)
SECONDARYHLAAAHAL
Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution)
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAFAL
Other Recombinant Protein Biosimilars (non-mAb, non-hormone)

Keywords

  • Biosimilar pharmaceuticals
  • Biological drug manufacturing
  • Erythropoietin biosimilars
  • Oncology biosimilars
  • Biopharmaceutical distribution

Where Biosidus S.A. is headquartered

Location

Headquarters

HQ city
Buenos Aires
HQ country
Argentina
HQ region
Latin America

Offices9 records

Markets served

Biosidus S.A. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Proprietary Biosimilar Product Sales: Biosidus develops, manufactures, and commercializes its own portfolio of nine biosimilars. Revenue is generated through direct sales to healthcare systems, hospitals, pharmacies, and government procurement tenders across emerging markets in Latin America, Africa, Asia, and Eastern Europe.
  2. Distribution Licensing with Large Pharma Companies: Biosidus signs licensing and distribution agreements with large pharmaceutical companies (e.g., Sandoz) for supplemental biologics. Biosidus supplies or licenses products while partners handle local commercialization and distribution, providing additional revenue streams and market access.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNo public pricing available — sold through institutional/government procurement channels

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Biosidus S.A. product offering

Product offering

Core offering

Biosidus is an Argentine biotechnology company that develops, manufactures, and commercializes a portfolio of nine biosimilars and several small molecule pharmaceuticals. The biosimilar portfolio covers erythropoietin, filgrastim, lenograstim, somatropin, teriparatide, interferon beta, and agalsidase beta, treating chronic kidney disease, multiple sclerosis, cancer, growth disorders, and rare lysosomal storage disorders. The company operates fully integrated manufacturing in Argentina (drug substance, fill-finish, and logistics) and distributes through direct sales offices, joint ventures, and licensing partners across more than 60 emerging markets in Latin America, Africa, the Middle East, Asia, and Eastern Europe.

Product overview

Biosidus is a biotechnology company headquartered in Argentina that develops and commercializes a portfolio of 9 biosimilars and small molecule pharmaceuticals. The biosimilar portfolio includes erythropoietin products (Hemax and Hemax LD), filgrastim products (Neutromax and Lenobio), interferon beta products (Blastoferon, Escleroferon, and Bioferon), teriparatide (Osteofortil), and growth hormone (HHT). The small molecule portfolio includes azacitidine (Amilix), bortezomib (Bromadene), fingolimod (Biomonar), and buprenorphine (Restiva). The company operates integrated manufacturing facilities in Buenos Aires, Argentina, and distributes products to over 60 countries worldwide through a network of sales offices, joint ventures, and strategic partnerships.

Differentiator

Problem solved

Functional benefit

Brands

  • Hemax: Erythropoietin (EPO) biosimilar for treating anemia associated with chronic kidney disease. Available in multiple formulations including lyophilized powder (LD) and higher doses.
  • Neutromax
  • Lenobio
  • Osteofortil
  • HHT
  • Blastoferon
  • Escleroferon
  • Bioferon
  • Bromadene
  • Amilix
  • Biomonar
  • Restiva
  • Agalzyme
  • BioesVida

Products and services

  • Hemax (Erythropoietin) Erythropoietin biosimilar available in high-dose formulations (10K, 20K, 40K U.I.) for treating anemia associated with chronic kidney disease.
  • Hemax LD First lyophilized erythropoietin formulation that does not require cold chain storage. Available in low-dose formulations (1000-4000 U.I.) with over 130 million doses sold worldwide.
  • Neutromax Filgrastim biosimilar (rHuG-CSF) with 60% market presence in Argentina and leadership position in Brazil. Used for prevention of febrile neutropenia in chemotherapy patients.
  • Lenobio Glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF) for prevention of febrile neutropenia and mobilization of peripheral blood stem cells.
  • Osteofortil First teriparatide biosimilar with a comparative clinical trial of efficacy and safety versus innovator. Pre-filled syringes containing 20 mcg teriparatide for osteoporosis treatment.
  • HHT (Somatropin) Somatropin (human growth hormone) biosimilar available in lyophilized powder formulations (4 UI and 16 UI). Used for growth hormone deficiency in children with over 20 years of clinical experience.
  • Blastoferon Interferon beta 1a biosimilar (European standard) launched in Argentina in 2005. Pre-filled syringes with 22 mcg or 44 mcg doses for treating relapsing remitting multiple sclerosis.
  • Escleroferon Interferon beta 1a biosimilar with once-weekly dosing. Pre-filled syringes containing 30 mcg for multiple sclerosis treatment.
  • Bioferon Interferon biosimilar with broad-spectrum antiviral properties. Available in 3, 5, and 10 mIU vial formulations for reconstitution.
  • Agalzyme Agalsidase beta biosimilar for the treatment of Fabry disease. Available in 5 mg and 35 mg vials for intravenous infusion.
  • Amilix Azacitidine small molecule drug for adult patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia who are not eligible for hematopoietic stem cell transplantation.
  • Bromadene Bortezomib small molecule for front-line treatment of symptomatic multiple myeloma patients. Supplied as 3.5 mg sterile lyophilized powder for reconstitution.
  • Biomonar Fingolimod small molecule - first orally administered treatment for active relapsing remitting multiple sclerosis with over 10 years of real-life experience.
  • Restiva Buprenorphine transdermal patches for treatment of moderate to severe pain not responsive to non-opioid analgesics. Available in 5, 10, and 20 mg doses.

Quantifiable outcome

  • 130 million doses sold globally since launch for Hemax erythropoietin biosimilar
  • +5 more outcomes

Companies that use Biosidus S.A.

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Biosidus S.A. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Biosidus S.A. partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Mubadala BiocoreChannel Partner/ Reseller/ Distributor · 24 June 2026Biosidus signed a licensing and supply agreement with Mubadala Bio to introduce a portfolio of biologic therapies in the UAE through Mubadala Bio's biologics platform DiabTec. The agreement was signed at BIO International Convention 2026 and witnessed by Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi. The collaboration covers therapies across endocrinology, nephrology, and oncology including epoetin alfa, filgrastim, interferon beta, and somatropin.
  • SandozcoreChannel Partner/ Reseller/ DistributorSandoz signed an agreement with Biosidus for the commercialization and distribution of current products and future launches in Argentina. This partnership extends Biosidus's market reach within Argentina through Sandoz's established pharmaceutical distribution network.
  • Brazil Partner (Local Production)coreStrategic or Co-development PartnerPartnership in Brazil enabling local production and distribution of Biosidus biosimilars, greatly enhancing market presence in one of Latin America's largest pharmaceutical markets.
  • Algeria Partner (Packaging & Distribution)coreChannel Partner/ Reseller/ DistributorCollaboration in Algeria for packaging and distribution of Biosidus biosimilars. This partnership established Biosidus as a dominant player with over 50% market share in certain segments in Algeria. The new facility in Algeria handles packaging initially and will eventually move toward full local production.

Scale indicators12 records

Recent moves11 records

Expansion highlights8 records

Biosidus S.A. competitors and assessment

Company assessment

Broad incumbents

  • Sandoz (Novartis): Global biosimilar and generics leader with a deep biosimilar portfolio across oncology, immunology and endocrinology. Comparable as a biosimilar incumbent and Biosidus's distribution partner in Argentina, but with vastly broader molecule coverage and global reach.
  • Teva Pharmaceutical Industries: Global generics and specialty pharma company with biosimilars (rituximab, trastuzumab) and broad emerging-market presence. Comparable on the biosimilar plus generics hybrid model and emerging-market distribution.
  • Amgen: Global biopharmaceutical originator that has both developed originator biologics and a growing biosimilar portfolio (e.g., adalimumab, bevacizumab, trastuzumab). Comparable as a major player in both originator biologics and biosimilars, with manufacturing scale Biosidus aspires to.

Direct peers

  • Celltrion: South Korea-headquartered biosimilar pioneer, leading global supplier of infliximab, rituximab, trastuzumab and adalimumab biosimilars. Directly comparable to Biosidus as a vertically integrated biosimilar developer with strong emerging-market commercial footprint.
  • Samsung Bioepis: Joint venture between Samsung Biologics and Biogen developing biosimilars in oncology, immunology and ophthalmology (etanercept, infliximab, adalimumab, trastuzumab, ranibizumab). Comparable as a focused biosimilar developer competing on cost and quality in regulated and emerging markets.
  • Dr. Reddy's Laboratories: Indian generics and biosimilar company with biosimilars in oncology (rituximab, bevacizumab, pegfilgrastim) and a strong emerging-market commercial network. Comparable to Biosidus on biosimilar pipeline and emerging-market distribution model.
  • mAbxience: Argentina-headquartered biosimilar developer (part of Insud Pharma group) producing monoclonal antibody biosimilars for global markets. The closest geographic and business-model peer to Biosidus — Argentine biosimilar company with international commercialization.
  • Biocon: India-based global biosimilar manufacturer with a portfolio covering insulin, trastuzumab, bevacizumab, pegfilgrastim and other recombinant biologics. Comparable to Biosidus as a focused biosimilar developer serving price-sensitive markets, though at much larger scale and broader molecule coverage.

Emerging players

  • Shanghai Henlius Biotech: Chinese biosimilar developer with approvals in China, Europe and emerging markets (rituximab, trastuzumab, adalimumab, bevacizumab). Comparable as a newer biosimilar entrant expanding into Latin America, Africa and Asia with cost-competitive biologics.
  • Hetero Drugs: Indian generics and biosimilar manufacturer with biosimilars in oncology (rituximab, bevacizumab) and a strong public-procurement track record in emerging markets. Comparable to Biosidus on cost-competitive biosimilars for tender-driven healthcare systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Biosidus S.A. social profiles

Digital presence

Biosidus S.A. compliance and trust

Trust signal

Compliance2 records

Biosidus S.A. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biosidus S.A. leadership team

Management profile

Number of profiles

Profiles4 records

Biosidus S.A. funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biosidus S.A. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosidus S.A.

What does Biosidus S.A. do?

Biosidus is an Argentine biotechnology company that develops, manufactures, and commercializes a portfolio of nine biosimilars and several small molecule pharmaceuticals. The biosimilar portfolio covers erythropoietin, filgrastim, lenograstim, somatropin, teriparatide, interferon beta, and agalsidase beta, treating chronic kidney disease, multiple sclerosis, cancer, growth disorders, and rare lysosomal storage disorders. The company operates fully integrated manufacturing in Argentina (drug substance, fill-finish, and logistics) and distributes through direct sales offices, joint ventures, and licensing partners across more than 60 emerging markets in Latin America, Africa, the Middle East, Asia, and Eastern Europe.

Is Biosidus S.A. a public or private company?

Biosidus S.A. is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biosidus S.A. founded?

Biosidus S.A. was founded in 1983. It employs 501 to 1,000 people.

Where is Biosidus S.A. based?

Biosidus S.A. is headquartered in Buenos Aires, Argentina, in the Latin America region.

How does Biosidus S.A. make money?

Two revenue lines are on record. Proprietary Biosimilar Product Sales are the primary driver. The others are distribution Licensing with Large Pharma Companies.

Who are Biosidus S.A.'s main competitors?

Broad incumbents on record are Sandoz (Novartis), Teva Pharmaceutical Industries and Amgen. Direct peers are Celltrion, Samsung Bioepis, Dr. Reddy's Laboratories, mAbxience and Biocon. Emerging players are Shanghai Henlius Biotech and Hetero Drugs.

Does Biosidus S.A. have an API?

No public API is recorded for Biosidus S.A..

What industry is Biosidus S.A. in?

Biosidus S.A.'s product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAAAHAK, Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration), with a secondary code of HLAAAHAL, Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBiosidus zwiększa moce produkcyjne w zakresie leków biologicznych i wzmacnia globalne możliwości dostaw agalzydazy betaArgentine biotechnology firm Biosidus announced on August 27, 2026 the start of a new facility equipped with bioreactors, expanding its production capacity for biologics and its ability to meet international demand. The company's agalsidase beta, a biologic enzyme therapy for Fabry disease, was launched in Argentina in 2025. Biosidus said it is ready to evaluate special supply needs where regulations permit.PR NewswireBiosidus rozširuje výrobnú kapacitu biologických liečiv a možnosti globálnych dodávok agalsidázy betaBiosidus, an Argentine biotechnology firm with over four decades of experience in biosimilar drug development and manufacturing, announced on August 27, 2026 that its new bioreactor facility is operational, raising production capacity for its biologics. The company said the expansion strengthens its ability to meet potential international demand for agalsidase beta, a biosimilar enzyme therapy for Fabry disease launched in Argentina in 2025.PR NewswireBiosidus étend sa capacité de production de médicaments biologiques et renforce ses capacités d'approvisionnement mondiales en agalsidase bêtaArgentine biotechnology firm Biosidus announced on August 27, 2026 that its new bioreactor plant is operational, expanding its capacity to produce biological medicines and strengthening its global supply capabilities. The expansion supports its biosimilar agalsidase beta, an enzyme replacement therapy for Fabry disease launched in Argentina in 2025. The company said it will continue developing its program internationally and evaluating exceptional supply needs where regulations allow.PR NewswireSpolečnost Biosidus rozšiřuje výrobní kapacitu biologických léčiv a posiluje globální dodavatelské kapacity pro agalsidázu betaArgentine biotechnology firm Biosidus announced on August 27, 2026 that its new bioreactor facility is operational, raising its capacity for biologics and strengthening supply of agalsidase beta, a biosimilar enzyme therapy for Fabry disease developed and manufactured in Argentina. The company said it is prepared to evaluate special delivery requests in markets where regulatory procedures allow.PR NewswireBiosidus расширяет мощности по производству биопрепаратов и укрепляет глобальные возможности поставок агалсидазы бетаArgentine biotech company Biosidus announced on August 27, 2026 that its new bioreactor plant is operational, expanding its biopreparations production capacity and strengthening its ability to meet potential international demand. The company's agalsidase beta, a biosimilar used in enzyme replacement therapy for Fabry disease, was launched in Argentina in 2025. Biosidus said it is ready to engage partners and health authorities seeking reliable agalsidase beta supply.FinanzNachrichten.deEQS-News: Biosidus erweitert seine Produktionskapazitäten für Biologika und stärkt seine weltweiten Lieferkapazitäten für Agalsidase betaBiosidus, an Argentine biotechnology company, announced on 27 August 2026 that its new bioreactor facility is operational, raising its biologics production capacity and strengthening its ability to meet potential international demand. The company's Agalsidase beta, a biosimilar enzyme replacement therapy for Fabry disease, was launched in Argentina in 2025. Biosidus said it is ready to evaluate supply agreements with partners and health authorities.PR NewswireBiosidus erweitert seine Produktionskapazitäten für Biologika und stärkt seine weltweiten Lieferkapazitäten für Agalsidase betaBiosidus, an Argentine biotechnology company, announced on August 27, 2026 that its new bioreactor facility is operational, raising its biologics production capacity and strengthening its ability to meet potential international demand. The company's Agalsidase beta, a biosimilar enzyme replacement therapy for Fabry disease, was launched in Argentina in 2025. Biosidus said it will evaluate partnerships and health authorities to provide reliable supply sources.MorningstarBiosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase betaBiosidus announced its new bioreactor plant is operational, increasing biologics production capacity and reinforcing supply for agalsidase beta. The company, which launched the biosimilar in Argentina in 2025, is prepared to engage with partners and health authorities evaluating sustainable supply sources.AijournBiosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase betaBiosidus, an Argentine biotechnology company, announced on August 26, 2026 that its new bioreactor plant is operational, raising its biologics production capacity and supporting potential international demand for its agalsidase beta biosimilar for Fabry disease. The company launched the drug in Argentina in 2025 and said it is prepared to evaluate extraordinary supply requirements where regulatory pathways allow.PR Newswire APACBiosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase betaBiosidus, an Argentine biotechnology firm, said on August 27, 2026 that its new bioreactor plant is operational, raising its biologics production capacity and supporting potential international demand for its agalsidase beta biosimilar for Fabry disease. The company launched the drug in Argentina in 2025 and is available to evaluate extraordinary supply requirements where regulatory pathways allow.